Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® ( bempedoic acid ) in Oral and Poster Presentations at the AHA Scientific Sessions 2025 - Esperion Therapeutics ( NASDAQ:ESPR )
- Analysis of Patients from CLEAR Outcomes Receiving No Other Background Lipid Lowering Therapies, Bempedoic Acid Alone Reduced MACE-4 by 14% Compared to Placebo - - An Exploratory Analysis of CLEAR Outcomes Reports Patients Who Took Bempedoic Acid Were 42% Less Likely to Experience Venous ...
ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down
Esperion's Q3 loss widens despite a 69% jump in revenues. Mixed results and investor jitters probably drag ESPR shares down 15%.
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635 ( c ) ( 4 )
ANN ARBOR, Mich., Nov. 06, 2025 ( GLOBE NEWSWIRE ) -- Esperion ( NASDAQ: ESPR ) today announced that on November 4, 2025, the Company granted 23 new employees 77,650 restricted stock units ( RSUs ) under Esperion's 2017 Inducement Equity Incentive Plan.
DoorDash Posts Downbeat Q3 Earnings, Joins elf Beauty, Duolingo, HubSpot And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Acadia Healthcare Co ( NASDAQ:ACHC ) , ACV Auctions ( NYSE:ACVA )
U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 0.1% on Thursday. Shares of DoorDash Inc ( NASDAQ:DASH ) fell sharply in pre-market trading after the company reported mixed third-quarter financial results.
Esperion Therapeutics ( ESPR ) Reports Q3 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -77.78% and +4.75%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Why Snap Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - ACV Auctions ( NYSE:ACVA ) , Alto Ingredients ( NASDAQ:ALTO )
Shares of Snap Inc ( NYSE:SNAP ) rose sharply in pre-market trading after the company reported better-than-expected third-quarter financial results. Snap reported quarterly losses of six cents per share, which beat the analyst estimate for losses of 12 cents.
Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update
- Q3 2025 Total Revenue Grew 69% Y/Y to $87.3 Million ...
Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer
- Brings Extensive Executive Leadership Driving Commercial Strategies That Enhance Sales and Marketing Performance ...
Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET. - Esperion Therapeutics ( NASDAQ:ESPR )
- Leading Cardiovascular Physician Experts to Explore Real-World Challenges and Impact on Patient Outcomes -
Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association ( AHA ) Scientific Sessions 2025
ANN ARBOR, Mich., Oct. 27, 2025 ( GLOBE NEWSWIRE ) -- Esperion ( NASDAQ: ESPR ) today announced that an oral presentation and a poster presentation have been accepted for presentation at the AHA Scientific Sessions 2025 in New Orleans, LA, November 7-10, 2025.
ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up
Esperion selects ESP-2001 as a preclinical candidate for primary sclerosing cholangitis, a rare liver disease, aiming to begin clinical studies in 2026.
ESPR Stock Drops 17% on Pricing of $75M Common Stock Offering
Esperion's stock sinks after pricing its common stock offering at $2.50 per share, a 19% discount to the prior close.
Dow Jumps Over 100 Points; US Crude Oil Inventories Increase - Critical Metals ( NASDAQ:CRML ) , Envoy Medical ( NASDAQ:COCH )
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Wednesday. The Dow traded up 0.32% to 46,751.12 while the NASDAQ rose 0.88% to 22,989.73. The S&P 500 also rose, gaining, 0.57% to 6,752.93. Information technology shares jumped by 1.1% on ...
Penguin Solutions Posts Q4 Earnings, Joins Esperion Therapeutics, Joby Aviation And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Esperion Therapeutics ( NASDAQ:ESPR ) , Archer Aviation ( NYSE:ACHR )
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 0.1% on Wednesday. Shares of Penguin Solutions, Inc. ( NASDAQ:PENG ) fell sharply in today's pre-market trading following fourth-quarter results.
Why Confluent Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - Acurx Pharmaceuticals ( NASDAQ:ACXP ) , AlphaTON Capital ( NASDAQ:ATON )
Shares of Confluent Inc ( NASDAQ:CFLT ) rose sharply in pre-market trading. Confluent is exploring a sale after attracting acquisition interest from tech firms and private equity investors, according to Reuters. Confluent shares jumped 19.5% to $24.77 in the pre-market trading session.
Esperion Announces Pricing of Public Offering of Common Stock
ANN ARBOR, Mich., Oct. 07, 2025 ( GLOBE NEWSWIRE ) -- Esperion Therapeutics, Inc. ( "Esperion" ) ( Nasdaq: ESPR ) , a commercial stage biopharmaceutical company that focuses on developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated ...
ESPR Settles Nexletol/Nexlizet Patent Litigation With RDY, Stock Up
Esperion settles Nexletol and Nexlizet patent dispute with Dr. Reddy's, securing U.S. market exclusivity until 2040 and lifting its shares nearly 14%.
Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL® ( bempedoic acid ) and NEXLIZET® ( bempedoic acid and ezetimibe ) Prior to April 19, 2040 - Esperion Therapeutics ( NASDAQ:ESPR )
ANN ARBOR, Mich., Oct. 03, 2025 ( GLOBE NEWSWIRE ) -- Esperion ( NASDAQ:ESPR ) today announced that it has entered into a settlement agreement with Dr. Reddy's Laboratories, Inc. and its affiliate Dr. Reddy's Laboratories Ltd. ( together, Dr. Reddy's Laboratories ) .
Esperion Reaches Settlement Agreement with ANDA Filer, Dr. Reddy's Laboratories, Not to Market Generic Versions of NEXLETOL® ( bempedoic acid ) and NEXLIZET® ( bempedoic acid and ezetimibe ) Prior to April 19, 2040
ANN ARBOR, Mich., Oct. 03, 2025 ( GLOBE NEWSWIRE ) -- Esperion ( NASDAQ: ESPR ) today announced that it has entered into a settlement agreement with Dr. Reddy's Laboratories, Inc. and its affiliate Dr. Reddy's Laboratories Ltd. ( together, Dr. Reddy's Laboratories ) .
Esperion Partner Otsuka Receives Regulatory Approval to Market NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
- Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for ...
Top 2 Health Care Stocks That May Plunge This Month - Esperion Therapeutics ( NASDAQ:ESPR ) , Enerflex ( NYSE:EFXT )
As of Sept. 5, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices ...
Esperion's Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias
- Bempedoic Acid Receives Strongest Endorsement from ESC/EAS Guidelines Based on Compelling and Practice-Changing Evidence ...
Are Options Traders Betting on a Big Move in Esperion Therapeutics Stock?
Investors need to pay close attention to Esperion Therapeutics stock based on the movements in the options market lately.
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635 ( c ) ( 4 )
ANN ARBOR, Mich., Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- Esperion ( NASDAQ: ESPR ) today announced that on August 5, 2025, the Company granted 12 new employees 73,500 restricted stock units ( RSUs ) under Esperion's 2017 Inducement Equity Incentive Plan.
ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises
Esperion posts narrower-than-expected second-quarter loss with revenues rising 12% and product sales jumping 42% year over year.
Esperion ( ESPR ) Q2 Revenue Jumps 12%
Esperion Therapeutics ( NASDAQ:ESPR ) , a specialty pharmaceutical company focused on cardiovascular disease, delivered higher-than-expected GAAP results in its latest earnings release. On August 5, 2025, it reported results. Revenue ( GAAP ) was $82.4 million, well above the analyst estimate of ...
Esperion Therapeutics ( ESPR ) Reports Q2 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of +88.24% and +24.28%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update
- Q2 2025 Total Revenue Grew 12% Y/Y to $82.4 Million ...
Earnings Preview: Crinetics Pharmaceuticals, Inc. ( CRNX ) Q2 Earnings Expected to Decline
CRINETICS PHARM (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neurocrine Biosciences ( NBIX ) Q2 Earnings and Revenues Beat Estimates
Neurocrine (NBIX) delivered earnings and revenue surprises of +8.16% and +5.72%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Esperion Therapeutics ( ESPR ) to Report a Decline in Earnings: What to Look Out for
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Esperion to Report Second Quarter 2025 Financial Results on August 5
ANN ARBOR, Mich., July 22, 2025 ( GLOBE NEWSWIRE ) -- Esperion ( NASDAQ: ESPR ) today announced it will report second quarter 2025 financial results before the market opens on Tuesday, August 5, 2025.
Aegle Therapeutics Names Industry Veteran Scott Braunstein, M.D. as Chairman of the Board
BOSTON, July 15, 2025 ( GLOBE NEWSWIRE ) -- Aegle Therapeutics, a clinical-stage dermatology-focused biopharmaceutical company developing novel therapies for those living with rare and severe skin diseases, today announced the appointment of Scott Braunstein, M.D., as Chairman of the Board.
Esperion Appoints Craig Thompson to Board of Directors - Esperion Therapeutics ( NASDAQ:ESPR )
ANN ARBOR, Mich., July 01, 2025 ( GLOBE NEWSWIRE ) -- Esperion ESPR today announced it has appointed Craig Thompson, Chief Executive Officer of Cerevance, to its Board of Directors. Mr. Thompson will serve as an independent director.
Esperion Appoints Craig Thompson to Board of Directors
Brings More Than Twenty Years of Biopharmaceutical Leadership Experience Brings More Than Twenty Years of Biopharmaceutical Leadership Experience ...
Why Is Esperion Therapeutics ( ESPR ) Up 28.6% Since Last Earnings Report?
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® ( bempedoic acid ) Prior to April 19, 2040 - Esperion Therapeutics ( NASDAQ:ESPR )
ANN ARBOR, Mich., June 02, 2025 ( GLOBE NEWSWIRE ) -- Esperion ESPR today announced that it has entered into a settlement agreement with Hetero USA, Inc. and its affiliates Hetero Labs Limited, Hetero Labs Limited Unit-V, and Honour Lab Limited ( together, Hetero USA ) .
Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® ( bempedoic acid ) Prior to April 19, 2040 - Esperion Therapeutics ( NASDAQ:ESPR )
ANN ARBOR, Mich., May 12, 2025 ( GLOBE NEWSWIRE ) -- Esperion ESPR today announced that it has entered into a settlement agreement with Micro Labs USA, Inc. and its affiliate Micro Labs Limited ( together, Micro Labs ) .
Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® ( bempedoic acid ) Prior to April 19, 2040
ANN ARBOR, Mich., May 12, 2025 ( GLOBE NEWSWIRE ) -- Esperion ( NASDAQ: ESPR ) today announced that it has entered into a settlement agreement with Micro Labs USA, Inc. and its affiliate Micro Labs Limited ( together, Micro Labs ) . This agreement resolves the patent litigation brought by ...
Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference
ANN ARBOR, Mich., May 09, 2025 ( GLOBE NEWSWIRE ) -- Esperion ( NASDAQ: ESPR ) today announced that the company will be participating in the webcasted H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, at 10 a.m. ET.
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635 ( c ) ( 4 )
ANN ARBOR, Mich., May 08, 2025 ( GLOBE NEWSWIRE ) -- Esperion ( NASDAQ: ESPR ) today announced that on May 7, 2025, the Company granted 15 new employees 49,300 restricted stock units ( RSUs ) under Esperion's 2017 Inducement Equity Incentive Plan.
Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® ( bempedoic acid ) and NEXLIZET® ( bempedoic acid and ezetimibe ) in Canada - Esperion Therapeutics ( NASDAQ:ESPR )
- Esperion to Receive an Upfront Payment, Near-Term Milestones and Tiered Royalties on Product Sales - - Further Expands Global Access to Bempedoic Acid Products and Provides Opportunity to Bring Innovative Preventative Therapy to 2.6 million Canadians Living with Diagnosed Heart Disease -
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down
Esperion reports mixed first-quarter 2025 results. Both earnings and revenues decline year over year. Stock falls.
CytoDyn Appoints Biotech Veteran Robert E. Hoffman as Chief Financial Officer - CytoDyn ( OTC:CYDY )
VANCOUVER, Washington, May 06, 2025 ( GLOBE NEWSWIRE ) -- CytoDyn Inc. CYDY ( "CytoDyn" or the "Company" ) , a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that Robert E.
Esperion Therapeutics ( ESPR ) Reports Q1 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -16.67% and 12.58%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical ( COLL ) Expected to Beat Earnings Estimates: Should You Buy?
Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Esperion Therapeutics ( ESPR ) to Report a Decline in Earnings: What to Look Out for
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Esperion to Participate in The Citizens Life Sciences Conference - Esperion Therapeutics ( NASDAQ:ESPR )
ANN ARBOR, Mich., April 25, 2025 ( GLOBE NEWSWIRE ) -- Esperion ESPR today announced that the company will be participating in the webcasted Citizens Life Sciences Conference on May 8, 2025, at 12:30 p.m. ET. The live webcast can be accessed on the investor and media section of the Esperion ...
Esperion to Participate in The Citizens Life Sciences Conference
ANN ARBOR, Mich., April 25, 2025 ( GLOBE NEWSWIRE ) -- Esperion ( NASDAQ: ESPR ) today announced that the company will be participating in the webcasted Citizens Life Sciences Conference on May 8, 2025, at 12:30 p.m. ET.
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics
Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics are part of the Zacks Industry Outlook article.
